宁泌泰胶囊联合头孢哌酮舒巴坦钠治疗急性肾盂肾炎的临床研究

目的探讨宁泌泰胶囊联合注射用头孢哌酮钠舒巴坦钠治疗急性肾盂肾炎的临床疗效。方法选取2015年2月—2016年2月武汉市黄陂区人民医院收治的急性肾盂肾炎患者84例,按照随机数字表法分为对照组和治疗组,每组各42例。对照组静脉滴注注射用头孢哌酮钠舒巴坦钠,1.5 g加入到生理盐水100 m L中,2次/d。治疗组在对照组基础上口服宁泌泰胶囊,4粒/次,3次/d。两组患者连续治疗2周。观察两组的临床疗效,比较两组的肾功能和肾间质纤维化情况。结果治疗后,对照组和治疗组的总有效率分别为76.19%、92.86%,两组比较差异有统计学意义(P0.05)。治疗后,两组血尿素氮(BUN)、血肌酐(Scr)和微量白蛋白(MAU)水平均显著下降,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标明显低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组血清转化生长因子β1(TGF-β1)和基质金属蛋白酶抑制剂-1(TIMP-1)水平均显著下降,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标明显低于对照组,两组比较差异具有统计学意义(P0.05)。结论宁泌泰胶囊联合注射用头孢哌酮钠舒巴坦钠具有较好的临床疗效,能明显改善患者肾功能,降低肾间质纤维化,具有一定的临床推广价值。

Clinical study on Ningmitai Capsules combined with cefoperazone sulbactam in treatment of acute pyelonephritis

Objective To evaluate the clinical effect of Ningmitai Capsules combined with Cefoperazone Sodium and Sulbactam Sodium for injection in treatment of acute pyelonephritis. Methods Patients (84 cases) with acute pyelonephritis in Huangpi District People's Hospital of Wuhan from February 2015 to February 2016 were randomly divided into control and treatment groups, and each group had 42 cases. Patients in the control group were iv administered with Cefoperazone Sodium and Sulbactam Sodium for injection, 1.5 g added into normal saline 100 mL, twice daily. Patients in the treatment group were po administered with Ningmitai Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and renal function and renal interstitial fibrosis in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 76.19% and 92.86%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of BUN, Scr, and MAU in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of TGF-β1 and TIMP-1 in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Ningmitai Capsules combined with Cefoperazone Sodium and Sulbactam Sodium for injection has clinical curative effect in treatment of acute pyelonephritis, can improve renal function, and decrease renal interstitial fibrosis, which has a certain clinical application value.